CN112725446B - 微卫星位点标志物及其应用 - Google Patents
微卫星位点标志物及其应用 Download PDFInfo
- Publication number
- CN112725446B CN112725446B CN202110045665.4A CN202110045665A CN112725446B CN 112725446 B CN112725446 B CN 112725446B CN 202110045665 A CN202110045665 A CN 202110045665A CN 112725446 B CN112725446 B CN 112725446B
- Authority
- CN
- China
- Prior art keywords
- marker analysis
- sample
- sequencing
- analysis window
- microsatellite
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108091092878 Microsatellite Proteins 0.000 title claims abstract description 93
- 239000003550 marker Substances 0.000 title claims description 128
- 208000032818 Microsatellite Instability Diseases 0.000 claims abstract description 104
- 238000012163 sequencing technique Methods 0.000 claims description 152
- 239000000523 sample Substances 0.000 claims description 148
- 238000004458 analytical method Methods 0.000 claims description 112
- 239000013068 control sample Substances 0.000 claims description 45
- 238000011156 evaluation Methods 0.000 claims description 24
- 238000013097 stability assessment Methods 0.000 claims description 23
- 238000011144 upstream manufacturing Methods 0.000 claims description 16
- 239000003153 chemical reaction reagent Substances 0.000 claims description 11
- 238000012360 testing method Methods 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 7
- 230000035790 physiological processes and functions Effects 0.000 claims description 4
- 230000003252 repetitive effect Effects 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 description 50
- 108020004414 DNA Proteins 0.000 description 30
- 238000000034 method Methods 0.000 description 29
- 238000001514 detection method Methods 0.000 description 27
- 210000001519 tissue Anatomy 0.000 description 24
- 239000003814 drug Substances 0.000 description 15
- 238000012216 screening Methods 0.000 description 15
- 238000003752 polymerase chain reaction Methods 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 229940079593 drug Drugs 0.000 description 11
- 206010009944 Colon cancer Diseases 0.000 description 9
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 9
- 230000035945 sensitivity Effects 0.000 description 9
- 201000011510 cancer Diseases 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 238000012165 high-throughput sequencing Methods 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 210000000601 blood cell Anatomy 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 238000000265 homogenisation Methods 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 238000012217 deletion Methods 0.000 description 5
- 230000037430 deletion Effects 0.000 description 5
- 208000008051 Hereditary Nonpolyposis Colorectal Neoplasms Diseases 0.000 description 4
- 201000005027 Lynch syndrome Diseases 0.000 description 4
- 238000007877 drug screening Methods 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 230000033607 mismatch repair Effects 0.000 description 4
- 229960002621 pembrolizumab Drugs 0.000 description 4
- 238000012070 whole genome sequencing analysis Methods 0.000 description 4
- 102100034157 DNA mismatch repair protein Msh2 Human genes 0.000 description 3
- 206010051922 Hereditary non-polyposis colorectal cancer syndrome Diseases 0.000 description 3
- 241000258241 Mantis Species 0.000 description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000004590 computer program Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 102100023990 60S ribosomal protein L17 Human genes 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 102100021147 DNA mismatch repair protein Msh6 Human genes 0.000 description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 2
- 208000017095 Hereditary nonpolyposis colon cancer Diseases 0.000 description 2
- 101001134036 Homo sapiens DNA mismatch repair protein Msh2 Proteins 0.000 description 2
- 101000968658 Homo sapiens DNA mismatch repair protein Msh6 Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000002357 endometrial effect Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 201000004101 esophageal cancer Diseases 0.000 description 2
- 210000001808 exosome Anatomy 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 229960005386 ipilimumab Drugs 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 238000007481 next generation sequencing Methods 0.000 description 2
- 229960003301 nivolumab Drugs 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 210000004976 peripheral blood cell Anatomy 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 208000029584 urinary system neoplasm Diseases 0.000 description 2
- 238000007482 whole exome sequencing Methods 0.000 description 2
- 238000012935 Averaging Methods 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 238000002944 PCR assay Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 208000037844 advanced solid tumor Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 229940125644 antibody drug Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 208000020790 biliary tract neoplasm Diseases 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- -1 hMLH1 Proteins 0.000 description 1
- 238000013115 immunohistochemical detection Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000037843 metastatic solid tumor Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- JMANVNJQNLATNU-UHFFFAOYSA-N oxalonitrile Chemical compound N#CC#N JMANVNJQNLATNU-UHFFFAOYSA-N 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000007480 sanger sequencing Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 206010044412 transitional cell carcinoma Diseases 0.000 description 1
- 229940055760 yervoy Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6858—Allele-specific amplification
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/30—Detection of binding sites or motifs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Bioinformatics & Computational Biology (AREA)
- Evolutionary Biology (AREA)
- Medical Informatics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Theoretical Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims (18)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110045665.4A CN112725446B (zh) | 2021-01-13 | 2021-01-13 | 微卫星位点标志物及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110045665.4A CN112725446B (zh) | 2021-01-13 | 2021-01-13 | 微卫星位点标志物及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112725446A CN112725446A (zh) | 2021-04-30 |
CN112725446B true CN112725446B (zh) | 2023-02-28 |
Family
ID=75592934
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110045665.4A Active CN112725446B (zh) | 2021-01-13 | 2021-01-13 | 微卫星位点标志物及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112725446B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114220483B (zh) * | 2021-12-03 | 2022-11-15 | 广州达安临床检验中心有限公司 | 用于微卫星稳定性状态检测的标志物、应用、方法及装置 |
CN114150067B (zh) * | 2022-02-07 | 2022-05-17 | 元码基因科技(北京)股份有限公司 | 确定用于检测微卫星不稳定状态的位点组合的方法、系统及探针组 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106755501B (zh) * | 2017-01-25 | 2020-11-17 | 广州燃石医学检验所有限公司 | 一种基于二代测序的同时检测微卫星位点稳定性和基因组变化的方法 |
CN107475375B (zh) * | 2017-08-01 | 2018-08-24 | 南京世和基因生物技术有限公司 | 一种用于与微卫星不稳定性相关微卫星位点进行杂交的dna探针库、检测方法和试剂盒 |
CN107526944B (zh) * | 2017-09-06 | 2018-08-24 | 南京世和基因生物技术有限公司 | 一种微卫星不稳定性的测序数据分析方法、装置及计算机可读介质 |
WO2019108807A1 (en) * | 2017-12-01 | 2019-06-06 | Personal Genome Diagnositics Inc. | Process for microsatellite instability detection |
CN109182525B (zh) * | 2018-09-29 | 2019-09-06 | 广州燃石医学检验所有限公司 | 一种微卫星生物标志物组合、检测试剂盒及其用途 |
CN109207594B (zh) * | 2018-09-29 | 2020-09-25 | 广州燃石医学检验所有限公司 | 一种基于二代测序的通过血浆检测微卫星稳定状态和基因组变化的方法 |
US20200118644A1 (en) * | 2018-10-15 | 2020-04-16 | Tempus Labs, Inc. | Microsatellite instability determination system and related methods |
CN111785324B (zh) * | 2020-07-02 | 2021-02-02 | 深圳市海普洛斯生物科技有限公司 | 一种微卫星不稳定分析方法及装置 |
CN112662740B (zh) * | 2021-01-13 | 2022-06-10 | 杭州瑞普基因科技有限公司 | 筛选微卫星位点的方法及其应用 |
-
2021
- 2021-01-13 CN CN202110045665.4A patent/CN112725446B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN112725446A (zh) | 2021-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106755501B (zh) | 一种基于二代测序的同时检测微卫星位点稳定性和基因组变化的方法 | |
US20230287511A1 (en) | Neuroendocrine tumors | |
US10998084B2 (en) | Sequencing data analysis method, device and computer-readable medium for microsatellite instability | |
US11142798B2 (en) | Systems and methods for monitoring lifelong tumor evolution field of invention | |
Julié et al. | Identification in Daily Practice of Patients With Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer): Revised Bethesda Guidelines-Based Approach: Versus: Molecular Screening | |
JP6513035B2 (ja) | 希少クロノタイプおよびその用途 | |
CN107475375A (zh) | 一种用于与微卫星不稳定性相关微卫星位点进行杂交的dna探针库、检测方法和试剂盒 | |
US20130324422A1 (en) | Detecting disease-correlated clonotypes from fixed samples | |
CN112725446B (zh) | 微卫星位点标志物及其应用 | |
EP2218794A1 (en) | Detection of instability in regions of genomic DNA containing simple tandem repeats | |
EP3693742B1 (en) | Methods of detecting prostate cancer | |
CN112662740B (zh) | 筛选微卫星位点的方法及其应用 | |
Gupta et al. | Evaluation of somatic hypermutation status in chronic lymphocytic leukemia (CLL) in the era of next generation sequencing | |
CN106906305A (zh) | lncRNA在胃腺癌诊断中的应用 | |
WO2019064063A1 (en) | BIOMARKERS FOR DETECTION OF COLORECTAL CANCER | |
CN108588201B (zh) | 一种结直肠癌西妥昔单抗耐药性痕量dna突变检测的方法及装置 | |
CN113061656A (zh) | Tet1基因突变在预测结肠癌患者对免疫检查点抑制剂疗法敏感性中的应用 | |
US20230374608A1 (en) | Breast cancer splice variants | |
US20130143207A1 (en) | Methods and compositions for identifying biomarkers useful in characterizing biological states | |
Kylätie | Validation of a Comprehensive Genomic Profiling Next-Generation Sequencing Assay for Diagnostic Use | |
US20210079481A1 (en) | Diagnostic assay for cancer | |
WO2024105220A1 (en) | Method for determining microsatellite instability status, kits and uses thereof | |
Maekawa et al. | A Pilot Proficiency Testing Study for Assessing Cancer Gene Panel using Patient Samples and Next-generation Sequencing in Japan | |
Xiao et al. | Microsatellite instability evaluation by a novel PCR‐based 8‐loci test kit in colorectal cancer | |
Pisapia et al. | DNA-Based Sequencing |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Xiao Shanshan Inventor after: Wang Tao Inventor after: Chang Yizhao Inventor before: Xiao Shanshan Inventor before: Wang Tao Inventor before: Chang Yizhao |
|
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Microsatellite Site Markers and Their Applications Granted publication date: 20230228 Pledgee: Guotou Taikang Trust Co.,Ltd. Pledgor: HANGZHOU REPUGENE TECHNOLOGY Co.,Ltd. Registration number: Y2024980004912 |